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Abstract 
Background 
The consequences of stroke must be assessed not only in terms of incidence and mortality rates, but 
also in terms of disability, which may persist long after the acute phase. 
Thrombolysis, if timely administered, can effectively reduce post-stroke disability. 
Aims 
The economic model presented herein aims to evaluate, in eligible patients, the effects of alteplase 
on post stroke disability and  related costs over three years. 
Methods 
The economic analysis was developed on the basis of four key components: clinical outcomes from 
international trials, economic consequences extracted from cost of illness studies, regulatory data 
from national and international agencies, and national epidemiological data. 
A population-level model estimated the difference in disability costs between patients treated with 
standard care versus those receiving thrombolytic therapy within 4.5 hours of acute ischemic stroke. 
The analysis covered  36 months from discharge. 
Results 
Reduced costs related to post-stroke disability were observed in treated patients compared to those 
receiving standard care (control). 
The overall savings were € 2,330.15 per average patient: € 1,445.81 during the first 18 months, € 
362.25 between 18-24 months, and  € 522.09  in the 24-36 months period. 
The overall savings on 3,174 Italian treated patients in 2013 were  € 7,395,907 over three years. 
Conclusion 
Our study reveals that performing thrombolytic therapy in eligible patients improves economic 
outcomes compared to patients receiving standard care. 
This model is useful for decision makers, both within and outside of the Italian national context, as a 
tool to assess the cost-effectiveness of thrombolysis in both short and long term period. 
 
Introduction 
Stroke is the second leading cause of death worldwide; in 2010 there were 16.9 million new stroke 
cases, 5.9 million deaths related to the disease, and 102 million Disability Adjusted Life Years 
(DALYs) lost.(1) Nevertheless the burden of stroke may be underestimated because of the 
consequences of stroke after the acute phase.(2). Even if the patients with acute strokes are managed 
optimally, they face the risk of severe disability (30%) and require institutional care (20%) after 
stroke.(3) Thus, the true impact of stroke must be viewed not only in terms of incidence and mortality 
rates, but also in terms of disability, which often persists for an extended time, often permanently, 
after stroke.(4) 
In Italy, the epidemiology of stroke is similar to that of other high-income countries, with ischemic 
stroke accounting for about 80% of total cases.(5) 
Thrombolysis using recombinant tissue Plasminogen Activator (rtPA), in Italy, is currently the only 
available evidence-based pharmacotherapy to treat acute ischemic stroke.(6) he European Medicine 
Agency approved alteplase for the fibrinolytic treatment of ischemic stroke for the European 
union(7); in Italy, the marketing authorization with the extended indication was approved in 2003. 
The Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST), which was 
completed in 2006, showed the safety of thrombolysis administered within 3 hours after ischemic 
stroke.(6) To ensure the maintenance of high levels of efficacy and safety in Italy, patients treated 
with alteplase must be registered in the “Safe Implementation of Thrombolysis in Stroke-Italian 
Stroke Thrombolysis Register” (SITS-ISTR)(7), which represents an extension of the previous SITS-
MOST study. 
Evaluations based on SITS-ISTR also demonstrated the safety and efficacy of thrombolytic treatment 
between 3 and 4.5 hours of onset of ischemic stroke.(8) Most recently, in 2013, hospital centers in 
Italy were authorized to administer alteplase up to 4.5 hours after acute ischemic stroke. 
Several trials, both ongoing(8) and completed(9), have demonstrated a positive risk/benefit ratio 
between 4.5 and 6 hours after the ischemic event. 
In each minute following a typical large vessel acute ischemic stroke, 1.9 million neurons, 14 billion 
synapses, and 12 km (7.5 miles) of myelinated fibers are destroyed.(10) The effectiveness of 
reperfusion measured by clot dissolution varies according to the time interval between ischemic 
stroke and alteplase administrationaccording to Meretoja et al., each minute of onset-to-treatment 
time saved could grant, on average, 1.8 days of extra healthy life.(11)   
The main parameter in evaluating the efficacy of thrombolytic treatment is the assessment of post-
stroke disability compared with standard care. Various qualitative scales are currently in use to 
measure disability following an ischemic stroke.(12) 
Data related to the effectiveness of thrombolytic therapy, included in our economic model, were 
extracted from international trials which use the Oxford Handicap Scale (OHS) as a measure of 
disability. Data costs related to the different levels of post stroke disability were extracted from 
economic studies which use the modified Rankin Scale (mRS). Both scales consist of 5 levels of 
disability, from no disability to complete dependence, and are substantially overlapping.(9) 
The burden of stroke has an impact on healthcare costs in addition to patient’s quality of life. In 
contrast to most of the diseases characterized by full recovery, however, the neuronal damage results 
in a disability that is minimally recoverable one year after the ischemic event. This means that it is 
necessary to evaluate the costs of stroke not only in the short term (30-90 days), but also in the 
medium and long term (1-3+ years). Thrombolysis is the only acute treatment that can effectively 
reduce post stroke disability. In many high income countries, like Italy, thrombolysis allows many 
patients to be effectively treated (13, 14) with consequent savings in both economic and clinical terms 
(quality of life). 
Aims 
The goal of the economic model was to demonstrate the reduction in post-stroke disability following 
thrombolysis and to quantify the associated costs over three years after the ischemic event using an 
increase in the rate of patients treated with alteplase on the total number of eligible patients. 
 
Materials and methods 
We developed a population-level model to estimate the difference of disability-costs between 
patients treated with standard care and those treated with thrombolytic therapy within 4.5 hours of 
acute ischemic stroke. 
All data were extracted from a scientific literature search. 
The economic evaluation was based on a societal perspective, which is the most appropriate in a 
public health system such as the Italian one. 
 
Study design – economic data 
The baseline cost data were estimated according to the following components: 
1. Direct healthcare costs, including: additional stroke-related hospital admissions, clinical 
consultations, diagnostic tests and procedures, domiciliary care, medical therapies, 
rehabilitation services, and other healthcare costs (i.e. appliances, aids) 
2. Direct non-healthcare costs, including informal care and paid care 
3. Indirect costs, including productivity losses 
 
These costs were obtained from a cost of illness analysis published in 2012 by Fattore et al.(15), 
which was based on a sample of 546 Italian patients with stroke; the study described in detail how 
the mRS level of post stroke disability influenced direct medical costs, direct non-medical costs, and 
indirect costs. 
Each class of costs (figure 1) was further divided into 3 disability levels: 
1. No or mild disability, mRS 0-2 
2. Moderate disability, mRS 3 
3. Severe disability, mRS 4-5 
Hence, each level was evaluated up to 18, 24, and 36 months. 
These time-points were chosen based on international health economic studies of intravenous 
thrombolysis treatment for acute ischemic stroke, indicating that intervention may be cost-effective 
in both the short term and in the long term(16, 17). However, the modeling of long-term costs and 
effects are subject to both uncertainty and methodological problems.(18) 
The percentage changes in costs for each class of disability after 12, 24, and 36 months were 
calculated from data published by Lopez et al.(19) 
Considering that clinical data included in our model showed the distribution of disability post-acute 
stroke at 18 months, we calculated the costs at 18 months, inferring that the variation between 12 and 
24 months was linear. 
 
Study design – clinical data 
The effectiveness of thrombolysis was assessed in terms of difference of post-stroke disability 
between patients treated with alteplase or standard care; data were extracted from the IST-3 trial.(9) 
This international, multicenter trial measured mortality and disability at 18 months between patients 
treated with or without alteplase for up to 6 hours after the ischemic event. 
According to data published in the IST-3 trial, thrombolysis does not significantly affect the mortality 
of post-stroke patients up to 18 months. Although mortality data do not substantially affect our 
economic analysis, we have had  to consider this parameter from  18 to 36 months using data from 
other published trials . 
The percentage changes of post stroke mortality, after 18 months,(table 1) were were extracted from 
the study by Slot et al.(20); the data on mortality published in this study are consistent with other 
international studies(21, 22) also conducted in the Italian population(23, 24), but more detailed and 
stratified by mRS classes. study did not evaluate the trend of disability after thrombolytic treatment, 
it did assess the probability of mRS class change, regardless of past events.(Table 1) 
In the second and third year after the ischemic event, trends of mortality were assumed to be different 
for each disability class and stable over time within the same mRS class, regardless of alteplase 
administration were equally likely to change their mRS disability level over time.. 
 
Study design – population 
The therapeutic indications of alteplase have changed in Italy in recent years. For most of 2013, the 
thrombolytic therapy could be administered within 3 hours after the ischemic event, but starting in 
October 2013, the window of treatment was extended to 4.5 hours. The leading Italian hospital of the 
SITS-MOST study prepares regular reports based on the number of thrombolytic treatments for stroke 
in Italy. Additionally, they publish the number of eligible patients who could have received alteplase 
in approved centers annually, thereby enabling the calculation of  the ratio between treated and 
eligible patients as a measure of efficiency of the Regions (efficiency = (n treated / n eligible) *100). 
Data published by the coordinating centers of the SITS-MOST study are calculated by utilizing an 
algorithm that extracts data from recent Italian clinical trials.(25, 26) 
Our analysis has been expanded to include the number of patients treated within the new 4.5 hour 
window for the 2013 calendar year. This is supported by the national SITS-MOST coordinating 
center, which demonstrated that increasing the therapeutic window to 4.5 hours for alteplase could 
nearly double the number of eligible patients to treatment. 
The population is calculated by the SITS-MOST coordinating center based on stroke incidence, the 
average time between onset of stroke and hospital arrival, and on the ”door to needle time,” which is 
the elapsed time  between arrival at the hospital and treatment administration. 
Finally, the last required data in our projections are those concerning the Italian population, which 
were extracted from the Italian Institute of STATistics (ISTAT) report.(27) 
 
Sensitivity analyses 
Sensitivity analyses were performed to test the robustness of the results of the model, given the 
uncertainty in the input values for the parameters. 
One-way sensitivity analyses were performed by changing rate of treated patients on eligible patients. 
By altering the input values across the range of possible values of 50, 75, and 100%, we identified 
how the model results would change. We considered the following possible values shown in the SITS-
MOST report that highlights the efficiency in every Italian region. 
1.87% in worst region in Italy 
33.23% in the best Italian region 
50% 75% and 100% like possible future better standard values. 
In addition, a 2-way sensitivity analyses was performed by simultaneously altering the input values 
for 2 parameters together to assess their combined effects on the results of the model. 
The first parameter was the direct non-healthcare costs at 12 months and indirect costs at 12 months. 
Direct healthcare, non-healthcare and indirect costs can affect various proportions on total costs as 
revealed in several cost of illness studies on stroke diseases. 
In the sensitivity analysis these costs were calculated as direct health care from Fattore et al., 
multiplied by values obtained by the study of Lopez: 2.134 and 0.385, respectively, and by value 
obtained by the Olesen’s study: 0.393 and 0.116, respectively. 
The second parameter was the % treated of eligible patients. 
 
Results 
According to 2011 ISTAT census report and most recent SITS-MOST Italian report, the Italian 
population in 2013 was 59,685,227. The eligible patients for alteplase therapy was calculated to be 
21,316. The number of patients treated with alteplase was 3,174, equal to 14.89% of eligible people. 
The direct healthcare, direct non-healthcare, and indirect costs by disability classes are shown in Table 
2. 
In our analysis conducted for disability classes, the estimated average cost per person increased from 
No or Mild disability to Severe disability. , the average cost for the patient with or without Mild 
disability is € 6,220.54, with Moderate is € 16,586.96 and with Severe is 42,365.74; in 18-24 months 
range is € 1,719.18, € 4,584.18 and € 11,708.73, respectively and from 24 to 36 months is € 3,052.49, 
€ 8,139.42 and € 20,789.38, respectively. 
Direct non-healthcare costs make up the largest proportion: 58% of the total average per person cost 
in each disability class after 18 months, 72% after 24 months, and 73% after 36 months. The indirect 
costs make up the smallest proportion:  4%, 3% and 3% after 18, 24 and 36 months, respectively. 
The estimated average cost per person is € 10,992.23 at 36 months after discharge for patient with No 
or Mild disability, € 29,310.55 for patients with Moderate disability and € 74,863.85 for patients with 
Severe disability. 
Consequently, the costs related to the post ischemic stroke disability in patients treated with alteplase 
compared with those treated with standard care (control) at 36 months from discharge are lower. 
The savings are € 7,395,907: € 4,588,996 for lower costs during the first 18 months, € 1,149,783 
during the period 18-24 months and € 1,657,129 after 36 months (Figure 2). 
Univariable (1-way = percent of treated on eligible patients) sensitivity analyses indicated that 
alteplase therapy is economically advantageous over the full range of possible percent treated of 
eligible patients values (Figure 2). 
Varying percent treated of eligible patients from 1.87%, to 14.89%, 33.23%, 50%, 75% and to 100%, 
the savings, in Italy after 36 months, increase from € 928,820 to € 7,395,907, € 16,505,193, € 
24,834,776,  € 37,252,165, and  € 49,669,553, respectively. 
Multivariable (2-way = percent treated + different distribution costs rates) sensitivity analyses 
revealed that thrombolysis is again advantageous (Figure 3). Using costs distribution from Lopez et 
al. study(19) in comparison with baseline data, we obtained a savings increase in a range € 558,526 
to € 29,867,695 with the change of percent of treated on eligible patients from 1.87% to 100%. 
Using European costs by Olesen’s et al.(28) in comparison with baseline cost data, savings decrease 
in a range from € 946,842 to € 50,633,257 with the change of percent treated on eligible patients from 
1.87% to 100%. 
 
Discussion 
Starting from the evidence (from IST-3 trial data) that thrombolysis reduces disability of patients after 
ischemic stroke, our study reveals that performing rtPA administration therapy in eligible patients 
improves economic outcomes compared to standard care. 
1-way sensitivity analyses assessed a range of savings from € 2,125,094 to € 47,122,696 in Italy and 
revealed that across these different thresholds most of the saving is in the 18 months period post-
discharge. 
2-way sensitivity analyses demonstrated that thrombolysis is also cost-effective for various changes 
in the direct non-healthcare costs at 12 months and indirect costs at 12 months. 
Additionally, savings were modelled conditional on alteplase administration within 6 hours of acute 
ischemic stroke. The eligible patients to thrombolysis are calculated as treatable after maximum of 
4.5 hours from stroke onset. As published by Saver et al., the sooner the reperfusion of the ischemic 
brain area occurs then less the permanent brain damage can occur.(10) 
Consequently, we consider that Italian differences of mRS disability classes between treated and 
untreated patients, at 18, 24, and 36 months after discharge, could be higher than data from IST-3 
trial. This potential consistent difference could significantly increase the savings arising from 
thrombolytic treatment in our projections according on higher efficacy of the thrombolysis and then 
of the lower post stroke disability. 
There are several limitations to our model. First, we modelled the difference of disability-costs 
between patients treated with standard care and treated with thrombolytic therapy on disability levels 
performed in one study (IST-3) without altering this outcomes in a sensitivity analysis, calling into 
question the generalizability of the model. This approach can be justified by a lack of adequate long-
term data. Currently, international studies provided evidence about post stroke disability states 
measured 90 days after treatment for acute ischemic stroke, but does not show longer-term data.(29) 
However this approach had the advantage of being based on an international and multicenter trial 
involving 12 countries and of assuming that thrombolysis lead to relevant improvement in disability 
so as confirmed by numerous other trials.(6, 7, 9) 
Second, our model used literature costs and survival data, so the savings could be higher or smaller 
in various countries. However, the model is sufficiently explained so as it allows the external 
validation. 
Lastly, our savings were calculated with time periods limited to 18-36 months and were estimated on 
the survival rates from Slot et al.(20) There was a trend of decreasing survival with increasing 
modified Rankin Scale at 12 months and these survival rates decrease in each category of functional 
status during the following years. Thrombolysis was associated with lower disability than standard 
care; consequently it is likely that savings may be continue until patients survive. 
Our economic model allows to calculate the potential savings from thrombolytic treatment in Italy, 
since we included national data about costs, epidemiology, and hospital efficiency related to the 
thrombolysis in our country. However, our study provides insight into the extent of the savings arising 
from the reduction of disability at 1, 2 and 3 years in a high-income country. As shown by our 
findings, the efficiency of Italian hospitals has plenty of scope for improvement, and considering the 
potential savings in both economic and in DALYs areas, it would be important to develop strategies 
that could significantly increase the ratio between treated and eligible patients. 
Several recent economic evaluations in literature, developed in different countries with different 
health care systems(13, 14, 30), agree that the increase in the rate of thrombolysis is cost-effective. 
However, differently from the economic studies above mentioned, our economic model is focused 
only on the savings arising from the reduction of post stroke disability after thrombolysis, because 
we think it is important to raise awareness of all stakeholders on this particular outcome. 
Finally, we believe our model is useful for decision makers, even outside of our national context as a 
helpful tool to assess the implementation of thrombolysis as cost-effective health technology in both 
the short and, especially, over the long term period. 
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 Oxford 
Handicap 
Scale 
Alteplase 
Therapy at 18 
months 
Traditional 
Therapy 
at 18 months 
Variation of survival 
percentage between 18 and 
24 months (%) 
Variation of survival 
percentage between 24 and 
36 months (%) 
0 0.11 0.07 -1.02 -6.25 
1 0.12 0.13 -2.02 -2.11 
2 0.12 0.11 -2.58 -8.70 
3 0.12 0.12 -5.73 -10.59 
4 0.07 0.1 -8.15 -16.88 
5 0.09 0.1 -8.11 -17.74 
Table 1. Percentage of patients in each OHS class after 18 months and variations by Slot et al.  at 
24 and 36 months from discharge 
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Disch
arge-
12 
mont
hs 
Discharge-18 months 18-24 months 24-36 months 
No or mild 
disability[0-2] 
1,964.
80 
2,359.72 176.83 
2,391.1
6 
3,606.84 222.54 426.36 1,247.11 45.71 742.69 2,220.50 89.30 
Moderate 
disability[3] 
5,239.
10 
6,292.16 471.52 
6,375.9
8 
9,617.57 593.41 1,136.88 3,325.41 121.89 1,980.38 5,920.92 238.12 
Severe 
disability[4-5] 
13,38
1.50 
16,071.18 1,204.34 
16,285.
29 
24,564.80 1,515.66 2,903.79 8,493.62 311.32 5,058.21 15,122.98 608.19 
 
*Direct-healthcare-costs  multiplied by 1.201 
**Direct-healthcare-costs multiplied by 0.09 
 
†Direct-healthcare-costs at 12 months + costs at 12 multiplied by 0.217 
††Direct-healthcare-costs at 12 months + costs at 12 months multiplied by 0.529 
†††Indirect-costs at 12 months + costs at 12 months multiplied by 0.259 
 
‡Direct-healthcare costs at 12 months multiplied by 0.217 
‡‡ Direct-healthcare costs at 12 months multiplied by 0.529 
‡‡‡ Indirect-costs at 12 months multiplied by 0.259 
 
§Direct-healthcare-costs at 12 months multiplied by 0.378 
§§Direct-healthcare-costs at 12 months multiplied by 0.941 
§§§Indirect-costs at 12 months multiplied by 0.505 
Table 2. Costs per patient included in the model 
 
 
